Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Cognitive Behavioral Intervention Helps Prevent Depression Among At-Risk Teens
Adolescents at an increased risk of depression who participated in a group cognitive behavioral intervention significantly reduced their symptoms and episodes of depression compared to teens who received usual care, although this effect was not seen for adolescents with a parent with current depression, according to a study in the June 3 issue of JAMA, a theme issue on child and adolescent health.

Osiris Therapeutics Reports Interim Data For COPD Stem Cell Study
Therapeutics, Inc. (NASDAQ:OSIR) announced six-month interim data from a Phase II clinical trial evaluating Prochymal, the Company"s proprietary formulation of adult mesenchymal stem cells, for the treatment of chronic obstructive pulmonary disease (COPD). Sixty-two patients were enrolled and are being followed for two years in the placebo-controlled study. At the six-month time-point, the data revealed several important findings.
News of the day
Florida-Based Organization Encourages Black Women To Be Tested For HIV
The one-year-old Florida-based organization Sistas Organizing to Survive on Saturday held a rally in Orlando that sought to raise awareness of HIV among black women and encourage them to be tested, the Orlando Sentinel reports. According to Debbie Tucci, coordinator for the Orange County Health Department"s HIV/AIDS program, one in 68 black women in the state is living with HIV/AIDS and many are unaware they are infected. AIDS has been a leading cause of death for black women ages 25 to 44 in the state for the past 15 years, the Sentinel reports (Ruano Gonzç¡lez, Orlando Sentinel, 6/21).
Oncology

Argenta Discovery And Porsolt Join Forces To Provide Fully-integrated CNS And Pain Contract Drug Discovery Services

Argenta Discovery and Porsolt announced they have entered into an alliance to provide unparalleled CNS and pain drug discovery services and expertise on a fee-for- service basis. The collaboration enables Argenta and Porsolt to undertake fully integrated CNS and pain-focused drug discovery programmes for their clients, from hit identification to development candidate nomination. Both companies bring a wealth of "Big Pharma" industry based experience and know-how in CNS and pain research. This alliance will leverage those key skills for its partners to ensure the rapid generation of high quality development candidates. Dr. Christopher Ashton, CEO of Argenta said, "Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projects, but we have been looking at ways of enhancing our capabilities in these important therapeutic areas. Argenta has partnered with Porsolt to provide clients with dedicated access to specialist CNS and pain models and expertise, offered by a world leader in the field. We have several ongoing contract research programmes in these therapeutic areas and a number of projects in the pipeline which are likely to benefit from Porsolt"s support and know-how. This alliance will enable Argenta to offer an even better integrated drug discovery service in the future. We are looking forward to working with Porsolt." Dr Mark Duxon, CEO of Porsolt added, "Porsolt is delighted to be entering into a partnership with Argenta to deliver full lead optimisation drug discovery on a contract research basis. Porsolt have recently announced a significant laboratory expansion in France and the Argenta partnership fits with our strategy of offering a diverse array of deal structure opportunities to suit the broad range of our clients" needs. Indeed, our increased business flexibility is entirely complementary to our client-oriented scientific expertise. Porsolt has always sought to deliver quality scientific solutions tailored to client needs. In this respect, we believe we have found a like minded partner in Argenta". Where there is a client need for outsourcing fully integrated drug discovery programmes for CNS and pain targets, Argenta and Porsolt offer a seamless drug discovery platform to the pharmaceutical industry, from hit identification to drug candidate selection. Should a client not be interested in a solution of this nature, both Porsolt and Argenta will continue to operate independently, offering their stand-alone contract research services spanning all therapeutic areas and drug target classes. Porsolt & Partners Pharmacology Argenta Discovery Ltd


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009